Ticker Launch
Sign inTry it free

Reverse merger · Pending · AMBX

Ambros Therapeutics, Inc.

Reverse merger with Werewolf Therapeutics, Inc. (HOWL)

Ambros Therapeutics, Inc. agreed to merge into Werewolf Therapeutics, Inc. (HOWL), a Nasdaq-listed clinical-stage biotech valued at $47.5 million in the merger, in a reverse merger that takes the private company public. The deal was announced on Aug 21, 2026. The combined company is expected to trade as Ambros Therapeutics (AMBX) on Nasdaq.

Ambros Therapeutics is a late-stage biotechnology company advancing neridronate for complex regional pain syndrome type 1 (CRPS-1). A pivotal Phase 3 trial, CRPS-RISE, is ongoing, and the drug holds FDA Breakthrough Therapy, Fast Track and Orphan Drug designations.

Status
Pending
Private company
Ambros Therapeutics, Inc.
Public company
Werewolf Therapeutics, Inc. (HOWL)
Public company business before
Nasdaq-listed clinical-stage biotech valued at $47.5 million in the merger
Announced
Aug 21, 2026
Combined company
Ambros Therapeutics (AMBX)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending reverse mergers